Swiss cannabis prices: comparing four contexts responsibly
Membership, pilot research, medical supply and unauthorised sales are distinct contexts. This overview establishes no current price bands, quality premiums or cheapest supplier.
Key facts
- Cheapest comparable channel: Not established here
- Substantiated quality premium: Not established here
- Basis for a price comparison: Product, date, unit and fees
Key takeaways
- No cheapest channel is inferred from unsubstantiated bands.
- The table awards no blanket legality or quality labels.
- The illustrative price index is not a substitute sample of market prices.
Interpretation
A price difference is meaningful only when quantity, composition, product form and included services are comparable. A gram of flower is not automatically comparable with a gram of extract or a ready-dosed medicine. Additional fees or different access rights can further change the comparison. A channel name is no proof of quality either: that requires product-specific records with an appropriate testing scope. This overview therefore makes unresolved prices visible and explains the different contexts. It confirms neither current club tariffs nor offers from a particular supplier. Any later update must document original evidence without hiding access and product differences behind a single ranking.
Limitations
- No collected sample of comparable prices. Without equivalent products, periods and fees, a ranking is not defensible.
- Not an exhaustive offer list, individual treatment advice or guarantee of availability.
- Unsubstantiated values mean neither zero francs nor an absence of market activity.
Data
| Comparison context | Substantiated standard price | Substantiated premium price | Legal context to check |
|---|---|---|---|
| Club membership | Not established here | Not established here | Membership does not replace sales authorisation |
| Authorised pilot study | Not established here | Not established here | Authorisation and individual participation conditions |
| Unauthorised sales | Not established here | Not established here | Not lawful access |
| Medical supply | Not established here | Not established here | Prescribing and medical care |
Methodology
A price observation needs a dated offer or transaction record identifying the product, quantity, unit, taxes and fees. These details must be comparable across channels. The former standard and premium bands came from shared preset figures; no traceable sample of the claimed market prices is documented here. Price fields therefore remain explicitly unresolved. The two official sources explain the law and pilot registry, not the prices in this table. Membership is not authorisation to sell cannabis subject to narcotics law. Pilot studies have their own participation conditions; medical supply belongs to prescribing and healthcare. Unauthorised sales are not presented as lawful access. Terms such as premium establish neither a uniform quality standard nor a measurable price uplift. The linked price-index model remains a separately labelled simulation and is not used as collected price evidence.
Sources
- FOPH: current legal framework for hemp and cannabis products — BAG / OFSP / UFSP / FOPH
- FOPH: authorised cannabis pilot trials — BAG / OFSP / UFSP / FOPH
Related data & articles
Parent
Same category
- Swiss cannabis price index — illustrative model — Prices dataset
Related datasets
- Swiss cannabis pilot projects: reviewed project register — Dataset · Pilot projects
Matching knowledge hubs
- Cannabis statistics Switzerland — Knowledge hub
- Consumer guides — for Switzerland — Knowledge hub
Articles
No collected sample of comparable prices. Without equivalent products, periods and fees, a ranking is not defensible.